10+
instalaciones · ≈16
—
0 valoraciones
2025-03-13
primer lanzamiento
2026-02-03
última actualización
Descripción
Study for Participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC
This app has been exclusively created for participants with Resected or Unresectable KRAS G12C-Mutant, NSCLC.
It contains Televisit functionality and allows participants to complete questionnaires.
The study is a Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
(Televisit tasks are not enabled by default and may be enabled as needed, by study officials.)
Novedades
Bug fixes and performance improvements
Detalles
| Versión | 5.4.1100.1-prod |
|---|---|
| Versión mínima de Android | 8.0 |
| Reseñas | 0 |
| Disponible en | Samoa Americana, Austria, Australia, Islas Aland, Bélgica, Bulgaria, San Bartolomé, Brasil, Canadá, Suiza, Chile, China y 53 más |
| Contactos del desarrollador | en el plan Business |
| Datos recogidos | 2026-11-15 |
Estos datos en la API
La ficha completa en JSON cuesta 1 token.
curl -H "X-API-Key: YOUR_KEY" \ "https://apkapi.com/api/v1/app?id=com.medable.lilly.jzqh"
